APRIL MAIYO: Open Payments
NPI 1528717659 · OVERLAND PARK, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,435 in 69 payments from 25 companies in 2025. Trend: 2023 $867 · 2024 $1,265 · 2025 $1,435
Food & beverage: $1,435
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 5 | $167 |
| Lilly USA, LLC | 8 | $159 |
| Novo Nordisk Inc | 9 | $151 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $125 |
| SHIELD THERAPEUTICS INC | 4 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $83 |
| Ascendis Pharma Endocrinology Inc | 2 | $57 |
| Dexcom, Inc. | 2 | $57 |
| Amgen Inc. | 2 | $46 |
Products named: TARPEYO, JARDIANCE, Ozempic, MOUNJARO, ACCRUFER, Kerendia, Yorvipath, Dexcom G6 Transmitter.
Industry payments across KS — which companies pay providers there.
